FORTIS Fortis Healthcare Q3 FY26 results (Oct–Dec 2025) and concall
Fortis Healthcare reported strong Q3 FY26 results with consolidated revenue growing 17.5% to INR2,265 crores and operating EBITDA increasing 34.8% to INR505 crores, driven by sustained growth in both hospital and diagnostics segments. Hospital EBITDA margins improved to 21.7%, while Agilus Diagnostics saw 8.3% revenue growth and significant margin expansion to 23.1%. However, PAT declined due to a one-off expense related to New Labour Codes, and some acquired/new facilities are experiencing initial occupancy drag, with Gleneagles units showing negative growth for the 9-month period.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 20.7%, net profit down 30.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 357 | 367 | 388 | 433 | 456 +28% | 443 +21% |
| EBITDA | 60 | 67 | 71 | 88 | 100 +67% | 99 +48% |
| Net profit | 40 | 40 | -42 | 52 | 125 +213% | 28 −30% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
